Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

PREDICT Offers a Heads-up on the Need for CT in Suspected Small Aortic Annuli

News Conference News EuroPCR 2025

PREDICT Offers a Heads-up on the Need for CT in Suspected Small Aortic Annuli

May 23, 2025

BATMAN Signals New Way to Prevent LVOT Obstruction in High-Risk TMVR Patients

News Conference News SCAI 2025

BATMAN Signals New Way to Prevent LVOT Obstruction in High-Risk TMVR Patients

May 07, 2025

News Industry News

Pi-Cardia Reports First Commercial Cases with ShortCut™

March 03, 2025

News Industry News

Pi-Cardia Receives FDA Market Clearance for ShortCut™

October 01, 2024

Risk Score IDs Patients Safe for Same-Day Discharge After Low-Risk TAVI

News Conference News NY Valves 2024

Risk Score IDs Patients Safe for Same-Day Discharge After Low-Risk TAVI

Michael O'Riordan

June 06, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Open SESAME? Transcatheter Myotomy Shows Promise for LVOT Obstruction

News Conference News CRT 2024

Open SESAME? Transcatheter Myotomy Shows Promise for LVOT Obstruction

March 12, 2024

Aficamten Delivers Positive Results in SEQUOIA-HCM

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

December 27, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

News Conference News TVT 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

Michael O'Riordan

June 09, 2023

MITRAL at 5 Years: TMVR for MAC, Failing Devices Shows Ongoing Impact

News Conference News EuroPCR 2023

MITRAL at 5 Years: TMVR for MAC, Failing Devices Shows Ongoing Impact

May 19, 2023

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

News Conference News STS 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

February 03, 2022

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

News Conference News PCR London Valves 2021

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Michael O'Riordan

November 25, 2021

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.